{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:04:53Z","timestamp":1790597093822,"version":"4.1.0"},"reference-count":14,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Glycogen storage disease type 1a (GSD 1a) is an inborn error of metabolism due to glucose-6-phosphatase deficiency. Treatment consists of frequent, carbohydrate-rich meals, intake of glucose polymers like uncooked cornstarch, or drip feeding in small infants. Although dietary treatment is challenging, it has improved the long-term outcomes for patients with GSD 1a. Nevertheless, several complications, including dyslipidaemia, remain difficult to manage, and early atherosclerosis with risk for ischemic stroke is a potential long-term concern. We propose bempedoic acid (BA) as a potential treatment option for dyslipidaemia in adult patients with GSD 1a. BA is an approved lipid-lowering therapy and may have additional beneficial metabolic effects in patients with GSD 1a. We hypothesize that BA may reduce malonyl-CoA concentrations and thereby alleviate the inhibition of mitochondrial fatty acid oxidation. This could potentially contribute to improved metabolic stability in patients with GSD 1a. Methods: Four adult female patients with GSD 1a and dyslipidaemia received BA at a dose of 180 mg once daily for 2\u20135 years. In this retrospective case series, we explored potential additional effects of BA treatment beyond its established lipid-lowering effect. Results: Under BA treatment, patients reported prolonged fasting periods, and carbohydrate intake could be reduced in some patients. Plasma lactate concentrations decreased during treatment, while triglyceride concentrations decreased in two patients but increased in the others. Two patients experienced a slight, clinically irrelevant increase in serum uric acid concentrations, a known adverse effect of BA. No other adverse effects were observed. Conclusions: In this retrospective, uncontrolled, single-center case series, BA was associated not only with its expected lipid-lowering effect, but also with potential improvements in metabolic control and prolonged fasting tolerance in adults with GSD 1a. However, these preliminary observations require confirmation in larger, prospective, controlled studies. Future studies should include standardized metabolic assessments and direct measurements of key metabolites involved in the pathophysiology of GSD 1a. Preclinical studies using appropriate animal models may further contribute to elucidating the underlying mechanisms and potential metabolic effects of BA.<\/jats:p>","DOI":"10.3390\/nu18193184","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:35:59Z","timestamp":1790595359000},"page":"3184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bempedoic Acid Treatment in Four Adult Patients with Glycogen Storage Disease Type 1a: A Retrospective, Exploratory Case Series"],"prefix":"10.3390","volume":"18","author":[{"given":"Julya","family":"Hempel","sequence":"first","affiliation":[{"name":"Clinic for Paediatric Kidney, Liver and Metabolic Diseases and Neuropaediatrics, Hannover Medical School, Children\u2019s Hospital, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Uta","family":"Meyer","sequence":"additional","affiliation":[{"name":"Clinic for Paediatric Kidney, Liver and Metabolic Diseases and Neuropaediatrics, Hannover Medical School, Children\u2019s Hospital, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-1154","authenticated-orcid":false,"given":"Christian","family":"Menke","sequence":"additional","affiliation":[{"name":"Clinic for Paediatric Kidney, Liver and Metabolic Diseases and Neuropaediatrics, Hannover Medical School, Children\u2019s Hospital, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3451-0488","authenticated-orcid":false,"given":"Charlotte","family":"Mindermann","sequence":"additional","affiliation":[{"name":"Clinic for Paediatric Kidney, Liver and Metabolic Diseases and Neuropaediatrics, Hannover Medical School, Children\u2019s Hospital, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Sabine","family":"Illsinger","sequence":"additional","affiliation":[{"name":"Clinic for Paediatric Kidney, Liver and Metabolic Diseases and Neuropaediatrics, Hannover Medical School, Children\u2019s Hospital, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-0852","authenticated-orcid":false,"given":"Anibh Martin","family":"Das","sequence":"additional","affiliation":[{"name":"Clinic for Paediatric Kidney, Liver and Metabolic Diseases and Neuropaediatrics, Hannover Medical School, Children\u2019s Hospital, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF02679988","article-title":"Historical highlights and unsolved problems in glycogen storage disease type 1","volume":"161","author":"Moses","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0021-9258(18)38504-1","article-title":"Glucose-6-phosphatase of the liver in glycogen storage disease","volume":"199","author":"Cori","year":"1952","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10545-014-9772-x","article-title":"Type I glycogen storage diseases: Disorders of the glucose-6-phosphatase\/glucose-6-phosphate transporter complexes","volume":"38","author":"Chou","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: A practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jocn.2010.03.026","article-title":"Ischemic stroke in an adult with glycogen storage disease type I","volume":"17","author":"Goulart","year":"2010","journal-title":"J. Clin. Neurosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1172\/JCI63967","article-title":"Malonyl-CoA: The regulator of fatty acid synthesis and oxidation","volume":"122","author":"Foster","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000283242","article-title":"Glycogen storage disease type 1: Impact of medium-chain triglycerides on metabolic control and growth","volume":"56","author":"Das","year":"2010","journal-title":"Ann. Nutr. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12263-023-00729-y","article-title":"Mitochondrial reprogramming in peripheral blood mononuclear cells of patients with glycogen storage disease type Ia","volume":"18","author":"Rossi","year":"2023","journal-title":"Genes Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12263-023-00733-2","article-title":"From common to rare: Repurposing of bempedoic acid for the treatment of glycogen storage disease type 1","volume":"18","author":"Das","year":"2023","journal-title":"Genes Nutr."},{"key":"ref_10","first-page":"e29891","article-title":"Bempedoic Acid\u2019s Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients with Coronary Artery Disease: A Systematic Review","volume":"14","author":"Goit","year":"2022","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic Acid: For Whom and When","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jimd.12654","article-title":"Gene therapy for glycogen storage diseases","volume":"47","author":"Koeberl","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1017\/jns.2021.73","article-title":"Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk","volume":"10","author":"Keirns","year":"2021","journal-title":"J. Nutr. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jimd.12380","article-title":"Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia","volume":"44","author":"Hoogerland","year":"2021","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/19\/3184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:50:58Z","timestamp":1790596258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/19\/3184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":14,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["nu18193184"],"URL":"https:\/\/doi.org\/10.3390\/nu18193184","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]}}}